person · Reporting owner

Casdin Private Growth Equity Fund II, L.P.

Disclosed activity across 1 company

Tapewire entity: 72209
SEC CIK: 0001891102

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
STANDARD BIOTOOLS INC.LAB · Entity 6116	Director	December 02, 2025	December 05, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

STANDARD BIOTOOLS INC.

Report date December 02, 2025 · Filed December 05, 2025

Jointly reported with Casdin Partners Master Fund, L.P., Casdin Capital, LLC, Casdin Partners GP, LLC, CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC, Casdin Private Growth Equity Fund II GP, LLC, Casdin Private Growth Equity Fund, L.P., Casdin Eli

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $0.001 par value per shareSEC Table I · non-derivative	IndirectSee footnote	71,875,000	Reported balance After 2025-12-02 transaction · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · 2025-12-02 · Purchase · Acquired 125,000 · Balance 71,875,000 F1: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.4050 to $1.4351. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F4: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP.
Common Stock, $0.001 par value per shareSEC Table I · non-derivative	IndirectSee footnote	71,950,000	Reported balance After 2025-12-03 transaction · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · 2025-12-03 · Purchase · Acquired 75,000 · Balance 71,950,000 F2: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.4403 to $1.4406. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F4: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP.
Common Stock, $0.001 par value per shareSEC Table I · non-derivative	IndirectSee footnote	72,100,000	Reported balance After 2025-12-04 transaction · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · 2025-12-04 · Purchase · Acquired 150,000 · Balance 72,100,000 F3: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.4331 to $1.4588. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F4: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP.
Common Stock, $0.001 par value per shareSEC Table I · non-derivative	IndirectSee footnote	13,939,637	Reported balance Holding disclosure · report date 2025-12-02 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 13,939,637 F6: The securities are owned directly by Casdin Private Growth Equity Fund II, L.P. (the "Equity Fund II") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund II, and (ii) Eli Casdin, the managing member of Casdin.
Common Stock, $0.001 par value per shareSEC Table I · non-derivative	IndirectSee footnote	2,744,219	Reported balance Holding disclosure · report date 2025-12-02 · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · Balance 2,744,219 F7: The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin.
Common Stock, $0.001 par value per shareSEC Table I · non-derivative	Direct	2,901,062	Reported balance Holding disclosure · report date 2025-12-02 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 2,901,062 F5: The securities are owned directly by Eli Casdin.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.4050 to $1.4351. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.

F2: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.4403 to $1.4406. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.

F3: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.4331 to $1.4588. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.

F4: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP.

F5: The securities are owned directly by Eli Casdin.

F6: The securities are owned directly by Casdin Private Growth Equity Fund II, L.P. (the "Equity Fund II") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund II, and (ii) Eli Casdin, the managing member of Casdin.

F7: The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
December 04, 2025 Filed Dec 5, 2025 01:59 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock, $0.001 par value per share	150,000	$1.45	$217,020.00	Disclosure SEC source: 0000919574-25-007243 · ownership.xml · nonDerivative · entry 3 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 72,100,000 F3 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.4331 to $1.4588. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F4 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
December 03, 2025 Filed Dec 5, 2025 01:59 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock, $0.001 par value per share	75,000	$1.44	$108,037.50	Disclosure SEC source: 0000919574-25-007243 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 71,950,000 F2 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.4403 to $1.4406. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F4 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
December 02, 2025 Filed Dec 5, 2025 01:59 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock, $0.001 par value per share	125,000	$1.42	$177,512.50	Disclosure SEC source: 0000919574-25-007243 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 71,875,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.4050 to $1.4351. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F4 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
November 25, 2025 Filed Nov 26, 2025 21:58 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock, $0.001 par value per share	7,550,000	$1.30	$9,838,405.00	Disclosure SEC source: 0000919574-25-007187 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 71,750,000 F2 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.30 to $1.3843. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F3 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
November 24, 2025 Filed Nov 26, 2025 21:58 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock, $0.001 par value per share	150,000	$1.43	$214,875.00	Disclosure SEC source: 0000919574-25-007187 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 64,200,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.4290 to $1.4396. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F3 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
November 20, 2025 Filed Nov 21, 2025 00:45 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock, $0.001 par value per share	450,000	$1.30	$586,260.00	Disclosure SEC source: 0000919574-25-007124 · ownership.xml · nonDerivative · entry 3 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 64,050,000 F3 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.2788 to $1.3500 . The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F4 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
November 19, 2025 Filed Nov 21, 2025 00:45 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock, $0.001 par value per share	350,000	$1.28	$448,910.00	Disclosure SEC source: 0000919574-25-007124 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 63,600,000 F2 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.2758 to $1.2870. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F4 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
November 18, 2025 Filed Nov 21, 2025 00:45 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock, $0.001 par value per share	275,000	$1.23	$339,405.00	Disclosure SEC source: 0000919574-25-007124 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 63,250,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.2247 to $1.2421. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F4 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
November 17, 2025 Filed Nov 17, 2025 23:58 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock, $0.001 par value per share	225,000	$1.22	$275,580.00	Disclosure SEC source: 0000919574-25-007087 · ownership.xml · nonDerivative · entry 3 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 62,975,000 F3 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.2175 to $1.2299. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F4 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
November 14, 2025 Filed Nov 17, 2025 23:58 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock, $0.001 par value per share	250,000	$1.24	$309,800.00	Disclosure SEC source: 0000919574-25-007087 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 62,750,000 F2 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.2364 to $1.2434. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F4 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
November 13, 2025 Filed Nov 17, 2025 23:58 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock, $0.001 par value per share	450,000	$1.20	$541,395.00	Disclosure SEC source: 0000919574-25-007087 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 62,500,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.1978 to $1.2098. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F4 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
November 12, 2025 Filed Nov 13, 2025 00:46 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock, $0.001 par value per share	375,000	$1.19	$445,837.50	Disclosure SEC source: 0000919574-25-006597 · ownership.xml · nonDerivative · entry 4 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 62,050,000 F4 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.1865 to $1.1913. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F5 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
November 11, 2025 Filed Nov 13, 2025 00:46 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock, $0.001 par value per share	300,000	$1.20	$358,800.00	Disclosure SEC source: 0000919574-25-006597 · ownership.xml · nonDerivative · entry 3 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 61,675,000 F3 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.1881 to $1.2053. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F5 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
November 10, 2025 Filed Nov 13, 2025 00:46 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock, $0.001 par value per share	275,000	$1.17	$321,915.00	Disclosure SEC source: 0000919574-25-006597 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 61,375,000 F2 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.1688 to $1.1732. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F5 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
November 07, 2025 Filed Nov 13, 2025 00:46 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock, $0.001 par value per share	225,000	$1.12	$252,765.00	Disclosure SEC source: 0000919574-25-006597 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 61,100,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.1153 to $1.1321. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F5 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
September 09, 2025 Filed Sep 12, 2025 01:03 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock, $0.001 par value per share	100,000	$1.29	$128,920.00	Disclosure SEC source: 0000919574-25-005636 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 60,875,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.2889 to $1.2895. The Reporting Persons undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
September 04, 2025 Filed Sep 5, 2025 23:08 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock, $0.001 par value per share	250,000	$1.28	$319,350.00	Disclosure SEC source: 0000919574-25-005603 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 60,775,000 F3 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.2621 to $1.2930. The Reporting Persons undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
September 03, 2025 Filed Sep 5, 2025 23:08 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock, $0.001 par value per share	250,000	$1.27	$316,400.00	Disclosure SEC source: 0000919574-25-005603 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 60,525,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.2414 to $1.2765. The Reporting Persons undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
August 26, 2025 Filed Aug 27, 2025 00:46 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock, $0.001 par value per share	125,000	$1.26	$157,937.50	Disclosure SEC source: 0000919574-25-005152 · ownership.xml · nonDerivative · entry 3 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 60,275,000 F1 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
August 25, 2025 Filed Aug 27, 2025 00:46 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock, $0.001 par value per share	200,000	$1.24	$248,180.00	Disclosure SEC source: 0000919574-25-005152 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 60,150,000 F2 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.2311 to $1.2475. The Reporting Persons undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F1 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
August 22, 2025 Filed Aug 27, 2025 00:46 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock, $0.001 par value per share	200,000	$1.26	$252,680.00	Disclosure SEC source: 0000919574-25-005152 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 59,950,000 F1 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
August 15, 2025 Filed Aug 16, 2025 01:18 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock	150,000	$1.22	$183,210.00	Disclosure SEC source: 0000919574-25-004979 · ownership.xml · nonDerivative · entry 3 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 59,750,000 F3 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.2179 to $1.2232. The Reporting Persons undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
August 14, 2025 Filed Aug 16, 2025 01:18 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock	133,220	$1.21	$161,542.57	Disclosure SEC source: 0000919574-25-004979 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 59,600,000 F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
August 13, 2025 Filed Aug 16, 2025 01:18 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock	75,000	$1.31	$98,280.00	Disclosure SEC source: 0000919574-25-004979 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 59,466,780 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.3075 to $1.3118. The Reporting Persons undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
February 28, 2025 Filed Mar 5, 2025 01:19 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	GrantCommon Stock	58,215	$1.07	$61,998.98	Disclosure SEC source: 0000919574-25-001777 · ownership.xml · nonDerivative · entry 4 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Casdin Amplify Fund, LP · CIK 0002028254 · 10% owner CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,806,470 F4 · shares: Represents Restricted Stock Units ("RSUs") that vest as to 25% on the last day of the last month of each fiscal quarter of 2025, subject to the Reporting Person's continued service through the applicable vesting date. F5 · price: The RSUs were issued to the Reporting Person, who elected to take RSUs in lieu of $62,000 in cash compensation for services as a board member. F6 · balance_after: Includes RSUs. F7 · ownership.direct: The securities are owned directly by Eli Casdin. Read SEC document
February 28, 2025 Filed Mar 5, 2025 01:19 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	OtherCommon Stock	545,000	$1.07	$580,425.00	Disclosure SEC source: 0000919574-25-001777 · ownership.xml · nonDerivative · entry 3 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Casdin Amplify Fund, LP · CIK 0002028254 · 10% owner CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F2 · kind: Represents a cross-trade, pursuant to which Casdin Amplify Fund, LP ("Amplify") transferred 545,000 shares of Common Stock to the Master Fund. F3 · ownership.nature: The securities were owned directly by Amplify and were deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to Amplify, (ii) the GP, the general partner of Amplify, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. Read SEC document
February 28, 2025 Filed Mar 5, 2025 01:19 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	OtherCommon Stock	545,000	$1.07	$580,425.00	Disclosure SEC source: 0000919574-25-001777 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Casdin Amplify Fund, LP · CIK 0002028254 · 10% owner CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 59,391,780 F2 · kind: Represents a cross-trade, pursuant to which Casdin Amplify Fund, LP ("Amplify") transferred 545,000 shares of Common Stock to the Master Fund. F1 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
February 28, 2025 Filed Mar 5, 2025 01:19 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock	4,820,959	$1.07	$5,134,321.34	Disclosure SEC source: 0000919574-25-001777 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Casdin Amplify Fund, LP · CIK 0002028254 · 10% owner CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 58,846,780 F1 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
August 27, 2024 Filed Aug 30, 2024 00:30 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock	250,000	$2.19	$546,750.00	Disclosure SEC source: 0000919574-24-005134 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Casdin Amplify Fund, LP · CIK 0002028254 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 54,025,821 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $2.1746 to $2.1953. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
August 26, 2024 Filed Aug 27, 2024 00:10 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock	150,000	$2.15	$322,455.00	Disclosure SEC source: 0000919574-24-004878 · ownership.xml · nonDerivative · entry 3 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Amplify Fund, LP · CIK 0002028254 · Director Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotet Disclosed balance after: 53,775,821 F4 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $2.1223 to $2.1719. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.direct: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
August 23, 2024 Filed Aug 27, 2024 00:10 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock	292,100	$2.13	$620,975.39	Disclosure SEC source: 0000919574-24-004878 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Amplify Fund, LP · CIK 0002028254 · Director Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 53,625,821 F3 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $2.115 to $2.1505. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.direct: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
August 22, 2024 Filed Aug 27, 2024 00:10 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock	307,900	$1.96	$602,806.62	Disclosure SEC source: 0000919574-24-004878 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Amplify Fund, LP · CIK 0002028254 · Director Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 53,333,721 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.9464 to $1.9587. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.direct: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
August 21, 2024 Filed Aug 22, 2024 00:47 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock	500,000	$1.90	$951,950.00	Disclosure SEC source: 0000919574-24-004812 · ownership.xml · nonDerivative · entry 3 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Casdin Amplify Fund, LP · CIK 0002028254 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 53,025,821 F4 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.8927 to $1.9364. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
August 20, 2024 Filed Aug 22, 2024 00:47 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock	500,000	$1.87	$936,700.00	Disclosure SEC source: 0000919574-24-004812 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Casdin Amplify Fund, LP · CIK 0002028254 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 52,525,821 F3 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.8596 to $1.8828. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
August 19, 2024 Filed Aug 22, 2024 00:47 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock	250,000	$1.85	$463,225.00	Disclosure SEC source: 0000919574-24-004812 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Casdin Amplify Fund, LP · CIK 0002028254 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 52,025,821 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.8279 to $1.8749. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
August 14, 2024 Filed Aug 16, 2024 23:52 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock	1,200,000	$1.59	$1,913,520.00	Disclosure SEC source: 0000919574-24-004802 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Amplify Fund, LP · CIK 0002028254 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 51,775,821 F1 · kind: The purchase of certain Shares reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934 with the sale of Shares at a price of $2.05 per share by an entity in which Casdin Capital, LLC ("Casdin"), Casdin Partners GP, LLC (the "GP") and Eli Casdin (collectively with Casdin and the GP, the "Disgorging Parties") had a pecuniary interest on the Disgorging Parties' Form 4 filed on June 21, 2024. The Disgorging Parties agree to pay to Issuer, upon settlement of the purchase, an additional $6.58 than the amount reported on the Disgorging Parties' Form 4 filed on August 6, 2024 and August 13, 2024, which represents the full amount of the profit realized by the Disgorging Parties, as a result of their pecuniary interest in the entity what made the sale referenced above, in connection with the short-swing transaction. F2 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.5516 to $1.605. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F3 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Master Fund, (ii) the GP, the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
August 13, 2024 Filed Aug 14, 2024 00:15 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock	550,000	$1.62	$890,560.00	Disclosure SEC source: 0000919574-24-004593 · ownership.xml · nonDerivative · entry 3 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Casdin Amplify Fund, LP · CIK 0002028254 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 50,575,821 F1 · kind: The purchase of certain Shares reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934 with the sale of Shares at a price of $2.05 per share by an entity in which Casdin Capital, LLC ("Casdin"), Casdin Partners GP, LLC (the "GP") and Eli Casdin (collectively with Casdin and the GP, the "Disgorging Parties") had a pecuniary interest on the Disgorging Parties' Form 4 filed on June 21, 2024. The Disgorging Parties agree to pay to Issuer, upon settlement of the purchase, an additional $57.27 than the amount reported on the Disgorging Parties' Form 4 filed on August 6, 2024, which represents the full amount of the profit realized by the Disgorging Parties, as a result of their pecuniary interest in the entity what made the sale referenced above, in connection with the short-swing transaction. F5 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.6151 to $1.6303. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F3 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Master Fund, (ii) the GP, the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
August 12, 2024 Filed Aug 14, 2024 00:15 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock	500,000	$1.64	$820,600.00	Disclosure SEC source: 0000919574-24-004593 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Casdin Amplify Fund, LP · CIK 0002028254 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 50,025,821 F1 · kind: The purchase of certain Shares reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934 with the sale of Shares at a price of $2.05 per share by an entity in which Casdin Capital, LLC ("Casdin"), Casdin Partners GP, LLC (the "GP") and Eli Casdin (collectively with Casdin and the GP, the "Disgorging Parties") had a pecuniary interest on the Disgorging Parties' Form 4 filed on June 21, 2024. The Disgorging Parties agree to pay to Issuer, upon settlement of the purchase, an additional $57.27 than the amount reported on the Disgorging Parties' Form 4 filed on August 6, 2024, which represents the full amount of the profit realized by the Disgorging Parties, as a result of their pecuniary interest in the entity what made the sale referenced above, in connection with the short-swing transaction. F4 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.6331 to $1.6978. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F3 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Master Fund, (ii) the GP, the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
August 09, 2024 Filed Aug 14, 2024 00:15 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock	525,408	$1.61	$848,481.38	Disclosure SEC source: 0000919574-24-004593 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Casdin Amplify Fund, LP · CIK 0002028254 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 49,525,821 F1 · kind: The purchase of certain Shares reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934 with the sale of Shares at a price of $2.05 per share by an entity in which Casdin Capital, LLC ("Casdin"), Casdin Partners GP, LLC (the "GP") and Eli Casdin (collectively with Casdin and the GP, the "Disgorging Parties") had a pecuniary interest on the Disgorging Parties' Form 4 filed on June 21, 2024. The Disgorging Parties agree to pay to Issuer, upon settlement of the purchase, an additional $57.27 than the amount reported on the Disgorging Parties' Form 4 filed on August 6, 2024, which represents the full amount of the profit realized by the Disgorging Parties, as a result of their pecuniary interest in the entity what made the sale referenced above, in connection with the short-swing transaction. F2 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.611 to $1.62. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F3 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Master Fund, (ii) the GP, the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
August 08, 2024 Filed Aug 10, 2024 01:34 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock	569,562	$1.64	$932,600.82	Disclosure SEC source: 0000919574-24-004339 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Amplify Fund, LP · CIK 0002028254 · Director Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 49,000,413 F3 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.565 to $1.68. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.direct: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
August 07, 2024 Filed Aug 10, 2024 01:34 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock	500,000	$1.57	$786,200.00	Disclosure SEC source: 0000919574-24-004339 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Amplify Fund, LP · CIK 0002028254 · Director Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 48,430,821 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.525 to $1.595. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.direct: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
August 05, 2024 Filed Aug 7, 2024 01:58 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock	200,000	$1.58	$316,780.00	Disclosure SEC source: 0000919574-24-004280 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Amplify Fund, LP · CIK 0002028254 · Director Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 47,930,821 F4 · kind: The purchase of Shares reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 200,000 Shares, with the sale of 200,000 shares of Issuer common stock at a price of $2.05 per share by an entity in which the Disgorging Parties had a pecuniary interest on the Disgorging Parties' Form 4 filed on June 21, 2024. The Disgorging Parties agreed to pay to Issuer, upon settlement of the purchase, $83.91 which represents the full amount of the profit realized by the Disgorging Parties, as a result of their pecuniary interest in the entity what made the sale referenced above, in connection with the short-swing transaction. F5 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.5664 to $1.5997. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F3 · ownership.direct: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Master Fund, (ii) the GP, the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. F3 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Master Fund, (ii) the GP, the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
August 02, 2024 Filed Aug 7, 2024 01:58 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock	1,000,000	$1.63	$1,631,900.00	Disclosure SEC source: 0000919574-24-004280 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Amplify Fund, LP · CIK 0002028254 · Director Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 47,730,821 F1 · kind: The purchase of Issuer's Common Stock ("Shares") reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 1,000,000 Shares, with the sale of 1,000,000 shares of Issuer common stock at a price of $2.05 per share by an entity in which Casdin Capital, LLC ("Casdin"), Casdin Partners GP, LLC (the "GP") and Eli Casdin (collectively with Casdin and the GP, the "Disgorging Parties") had a pecuniary interest on the date reported on the Form 4 filed on June 21, 2024 by the Disgorging Parties. The Disgorging Parties agreed to pay to Issuer, upon settlement of the purchase, $376.24 which represents the full amount of the profit realized by the Disgorging Parties, as a result of their pecuniary interest in the entity which made the sale referenced above, in connection with the short-swing transaction. F2 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.5462 to $1.6583. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F3 · ownership.direct: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Master Fund, (ii) the GP, the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. F3 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Master Fund, (ii) the GP, the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
June 18, 2024 Filed Jun 22, 2024 00:53 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	OtherCommon Stock	1,200,000	$2.05	$2,460,000.00	Disclosure SEC source: 0000919574-24-003795 · ownership.xml · nonDerivative · entry 3 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote. Disclosed balance after: 0 F5 · kind: Represents a cross-trade, pursuant to which Casdin FO1 transferred 1,200,000 shares of Common Stock to the Master Fund and Amplify. F6 · ownership.nature: The securities were owned directly by Casdin FO1 and were deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to Casdin FO1, (ii) the GP, the general partner of Casdin FO1, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. Read SEC document
June 18, 2024 Filed Jun 22, 2024 00:53 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	OtherCommon Stock	545,000	$2.05	$1,117,250.00	Disclosure SEC source: 0000919574-24-003795 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote. Disclosed balance after: 545,000 F3 · kind: Represents a cross-trade, pursuant to which Casdin FO1 transferred 545,000 shares of Common Stock to Casdin Amplify Fund, LP ("Amplify"). F4 · ownership.nature: The securities are owned directly by Amplify and are deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to Amplify, (ii) the GP, the general partner of Amplify, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. Read SEC document
June 18, 2024 Filed Jun 22, 2024 00:53 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	OtherCommon Stock	655,000	$2.05	$1,342,750.00	Disclosure SEC source: 0000919574-24-003795 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote. Disclosed balance after: 46,730,821 F1 · kind: Represents a cross-trade, pursuant to which Casdin Partners FO1-MSV, LP ("Casdin FO1") transferred 655,000 shares of Common Stock to Casdin Partners Master Fund, L.P. (the "Master Fund"). F2 · ownership.nature: The securities are owned directly by the Master Fund and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
May 23, 2024 Filed May 29, 2024 00:45 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock	100,000	$2.60	$260,000.00	Disclosure SEC source: 0000919574-24-003356 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 46,075,821 F1 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
May 22, 2024 Filed May 22, 2024 23:53 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock	150,000	$2.58	$387,735.00	Disclosure SEC source: 0000919574-24-003308 · ownership.xml · nonDerivative · entry 3 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 45,975,821 F4 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $2.5771 to $2.5865. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
May 21, 2024 Filed May 22, 2024 23:53 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock	350,000	$2.56	$895,930.00	Disclosure SEC source: 0000919574-24-003308 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 45,825,821 F3 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $2.5597 to $2.56. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document
May 20, 2024 Filed May 22, 2024 23:53 UTC	STANDARD BIOTOOLS INC. LAB · Entity 6116	PurchaseCommon Stock	100,000	$2.58	$258,130.00	Disclosure SEC source: 0000919574-24-003308 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 45,475,821 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $2.5791 to $2.5858. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.